Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$296.88 USD

296.88
2,410,872

+1.78 (0.60%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $296.81 -0.07 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs

by Zacks Equity Research

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.

Zacks Equity Research

Can Amgen Keep the Beat Streak Alive This Earnings Season?

by Zacks Equity Research

Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Zacks Equity Research

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron

by Zacks Equity Research

Pfizer, Eli Lilly, Amgen, Biogen and Regeneron are included in this Analyst Blog.

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Zacks Equity Research

Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?

by Zacks Equity Research

Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.

Kinjel Shah headshot

Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)

by Kinjel Shah

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Zacks Equity Research

Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Zacks Equity Research

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Kinjel Shah headshot

Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Zacks Equity Research

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.

Sheraz Mian headshot

Q1 Earnings Scorecard and Analyst Reports for Costco, American Express & Goldman Sachs

by Sheraz Mian

Today's Research Daily features the Q1 earnings season scorecard and updated research reports on Costco (COST), American Express (AXP) and Goldman Sachs (GS), and others.

Ahan Chakraborty headshot

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

by Ahan Chakraborty

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

Zacks Equity Research

Amgen (AMGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amgen (AMGN) Stock Moves -1.3%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) concluded the recent trading session at $273.68, signifying a -1.3% move from its prior day's close.

Zacks Equity Research

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Zacks Equity Research

Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

by Zacks Equity Research

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.

Zacks Equity Research

Here's Why Amgen (AMGN) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Mark Vickery headshot

Short Week Finishes with Netflix Q1 Beat

by Mark Vickery

We'd obviously welcome any positive news on the trade tariff front over the weekend, which starts tomorrow for the markets in observance of Good Friday.

Zacks Equity Research

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $277.29, denoting a -1.89% change from the preceding trading day.

Kinjel Shah headshot

Here's How You Should Play JNJ Stock After Q1 Earnings Beat

by Kinjel Shah

Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Kinjel Shah headshot

Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?

by Kinjel Shah

Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.

Zacks Equity Research

JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal

by Zacks Equity Research

J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.